VANCOUVER, BC, Oct. 13, 2020 /CNW/ - Sirona Biochem Corp.
(TSXV: SBM) (FSE: ZSB) (US-OTC:
SRBCF) ("Sirona") is pleased to announce that it
has signed an agreement with a top 10 global pharmaceutical company
("Company") to jointly test Sirona's novel skin care, dark
spot remover, TFC-1067, in a new clinical study. TFC-1067 will be
tested using a new higher concentration (0.4%) and advanced
formulation.
The clinical trial, launched October
5th, will run for a period of 12 weeks and
include a minimum of 125 participants. It will be managed by
Dermscan (a division of Eurofins), a global leader in cosmetic
clinical trials. The study's endpoint is to determine the
compound's ability to reduce hyperpigmentation or "dark spots" of
the skin.
Multiple parameters will be measured including the added effects
of the higher concentration of TFC-1067 and a boosted formulation.
The study is expected to complete in early 2021 with results in
February 2021. The study protocol was
established through a collaboration of the scientific teams of
TFChem, Sirona's wholly owned subsidiary and the Company's skincare
scientific team.
Following the study, the Company will have first access to the
clinical study results to assess potential use by its subsidiary
dermatology company.
"To have a partner of this magnitude assisting in the design and
financing of our clinical trial is a testament to the potential of
TFC-1067," said Dr. Howard Verrico,
CEO of Sirona Biochem. "We look forward to continuing our
relationship with their clinical team through the study as we
evaluate the higher dose and improved formulation of the compound.
TFC-1067 has been clinically proven to selectively lighten dark
spots and blend them into surrounding skin tone. The ability to
lessen visibility of dark spots while preserving underlying skin
tone safely is a unique consumer benefit."
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.